Teva Pharmaceutical Industries Limited (TEVA)
Automate Your Wheel Strategy on TEVA
With Tiblio's Option Bot, you can configure your own wheel strategy including TEVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TEVA
- Rev/Share 14.4969
- Book/Share 16.299
- PB 2.9472
- Debt/Equity 2.5641
- CurrentRatio 1.064
- ROIC 0.0698
- MktCap 19982731689.0
- FreeCF/Share 0.8596
- PFCF 20.2665
- PE -127.4767
- Debt/Assets 0.4366
- DivYield 0
- ROE -0.0258
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TEVA | Goldman | -- | Buy | -- | $24 | June 6, 2025 |
| Initiation | TEVA | Truist | -- | Buy | -- | $25 | May 28, 2025 |
| Upgrade | TEVA | JP Morgan | Neutral | Overweight | -- | $23 | May 12, 2025 |
News
Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”
Published: August 19, 2025 by: Business Wire
Sentiment: Neutral
GOLETA, Calif.--(BUSINESS WIRE)--Teva unveils AW25 footwear collection.
Read More
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Positive
Teva is transforming, with management delivering on profit growth, specialty drug expansion, and improving its balance sheet—yet the stock remains undervalued. Specialty products like AUSTEDO and UZEDY are driving margin improvement, while partnerships and cost-cutting support a credible turnaround. Despite lingering legal and debt risks, Teva's low valuation offers a favorable risk/reward for patient investors willing to look past old headlines.
Read More
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
Read More
Teva CEO: Our supply chain puts us in a strong position
Published: July 30, 2025 by: CNBC Television
Sentiment: Positive
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.
Read More
Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript
Published: July 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Christopher J. Stevo - Senior Vice President of Investor Relations & Competitive Intelligence Eliyahu Sharon Kalif - Executive VP & CFO Eric A.
Read More
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Teva Pharm Q2 profit beats estimates as branded drugs gain
Published: July 30, 2025 by: Reuters
Sentiment: Positive
Teva Pharmaceutical Industries reported a higher than expected rise in second-quarter profit, helped by strong sales gains of its branded drugs to treat migraines, Huntington's disease and schizophrenia.
Read More
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.
Read More
Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevention study showed that AJOVY (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in reducing frequency, duration and severity of migraine attacks in patients with chronic and episodic migraine.1
Read More
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.
Read More
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
Published: June 16, 2025 by: PRNewsWire
Sentiment: Neutral
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Growth strategy TEL AVIV, Israel and SHANGHAI , June 16, 2025 /PRNewswire/ -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Read More
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Company Participants Richard D. Francis - President, CEO & Director Conference Call Participants Matthew Michael Dellatorre - Goldman Sachs Group, Inc., Research Division Matthew Michael Dellatorre Okay.
Read More
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.
Read More
Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript
Published: June 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Jefferies Global Healthcare Conference June 4, 2025 9:20 AM ET Company Participants Christine Fox - Executive VP of U.S. Commercial Business Eric A. Hughes - Executive VP of Global R&D and Chief Medical Officer Conference Call Participants Dennis Ding - Unidentified Company Dennis Ding Good morning.
Read More
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
Read More
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
TEVA starts IND-enabling studies for BD9, a dual-targeting multibody for asthma and eczema. Shares rise on the news.
Read More
TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
TEVA rises 12.9% in a month as investors react to mixed first-quarter results, cost-cutting plans and growing momentum in branded and biosimilar drug sales.
Read More
Why Investors Should Watch Teva Despite Regional Risks
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Despite the lack of cautious enthusiasm from retail investors in Teva, it continues to beat consensus estimates by wide margins and has once again raised its 2025 financial guidance. I highlight Austedo, Uzedy, the launch of biosimilars, and the more than successful development of duvakitug for the treatment of IBD in collaboration with Sanofi as key growth drivers. Moody's and Fitch also recently raised the Israeli pharmaceutical giant's credit ratings thanks to the continued strengthening of its balance sheet.
Read More
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it is increasing the maximum tender amount of its tender offer previously announced on May 19, 2025 from $2.0 billion (equivalent) aggregate cash purchase price (exclusive of accrued and unpaid interest) to approximately $2.25 billion (equivalent) aggregate cash purchase price (exclusive of accrued and unpaid interest) (the “Total Maximum Amount”).
Read More
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
Published: May 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the “Notes”). The principal amount of the offering was increased from the previously announced offering size of $2,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings (i) to fund the announced tender offers (collectively, the “Tender Offer”) to purchase, for cash, its 3.150% Senior Notes due 2026, 4.750% Sustainability-Linked Senior Notes due 2027, 3.750% Sustainability-Linked Senior Notes due 2027, 7.875% Sustainability-Linked Senior …
Read More
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
Published: May 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to BB+, with a stable outlook; from BB. Fitch's report cites Teva's progress in reducing debt and improving flexibility, expects continuous revenue growth from AUSTEDO and AJOVY, as well as Teva's biosimilar pipeline.
Read More
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,000,000,000 (equivalent) of senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior Notes (the “Euro Notes”) and Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”) and Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV” and, together with Teva Finance II and Teva Finance III, the “Issuers”) intend to offer USD-denominated Senior Notes (the “USD Notes” and, together with the Euro Notes, …
Read More
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) (the “Total Maximum Amount”) of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
Read More
Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
Teva's betting big on biosimilars and specialty drugs, with AUSTEDO and UZEDY leading the charge. Management's $700 million cost-cutting plan is on track, aiming for a 30% operating margin by 2027. Recent FDA wins, like SELARSDI, show Teva's pushing into high-margin markets.
Read More
TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
TEVA shares rise despite mixed first-quarter results. Teva lowers the higher end of its 2025 sales guidance while increasing the lower end of its EPS range.
Read More
Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says
Published: May 07, 2025 by: Barrons
Sentiment: Positive
The drugmaker reported first-quarter earnings that beat expectations and raised its full-year guidance.
Read More
Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties
Published: May 07, 2025 by: CNBC Television
Sentiment: Positive
Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, any pharma shortages in the U.S., and much more.
Read More
Teva Pharma climbs as earnings impress
Published: May 07, 2025 by: Proactive Investors
Sentiment: Positive
Shares in Teva Pharmaceutical Industries (NASDAQ:TEVA) rose 5% after publishing first-quarter earnings, where the Israeli company said US tariffs are expected to have an "immaterial impact". The Tel Aviv-based drugs maker reported revenue of $3.9 billion for the quarter, a 5% increase in local currency terms as key growth products continued to perform well, with operating income swinging to $519 million from a loss of $218 million a year ago.
Read More
Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q1 2025 Earnings Call May 7, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric A. Hughes - EVP, Global R&D and Chief Medical Officer Eli Kalif - EVP & CFO Conference Call Participants David Amsellem - Piper Sandler Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Ashwani Verma - UBS Investment Bank Christopher Schott - J.P.
Read More
Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
About Teva Pharmaceutical Industries Limited (TEVA)
- IPO Date 1982-02-16
- Website https://www.tevapharm.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Richard D. Francis
- Employees 37000